Strategy
← Earnings Calls
01
02
03
04 05 06
Tone
A1 A2 A3
INCY
FY2026 Q2
Raised
Incyte Corporation earnings call
Buzzberg read
Company no longer dependent on single asset, multiple growth drivers
Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement.
Buzzberg read Company no longer dependent on single asset, multiple growth drivers Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement. Read full analysisCollapse analysis
Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement.
- Incyte raised its full-year 2026 total net sales guidance to $5.13-$5.26B.
- The core business (ex-Jakafi) grew 44% YoY, driven by Opzelura, Niktimbo, Monjuvi, and Zynyz.
- Management emphasized a transition away from dependence on a single asset (Jakafi) toward a multi-product, late-stage pipeline.
JAKAFI Revenue$0.817BReported
OPSALURA Revenue$0.45BReported
Revenue$1.674B+32% QoQ
EPS$3.09Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Margins
Opsalura CMS settlement improves gross-to-net profile
Pipeline
Latarsabart could be a 'Hemlibra-like' opportunity
Show 3 more callouts
Pipeline
989 phase 3 in MF to start after FDA discussions
Pipeline
ESMO data expected to de-risk 734 in pancreatic cancer
Commercial
Jackify XR formulary coverage on track to 50-70%
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| JAKAFI Revenue | $0.817B | Reported |
| OPSALURA Revenue | $0.45B | Reported |
| Revenue | $1.674B | +32% QoQ |
| EPS | $3.09 | Reported |
| Operating margin | 41.69% | Reported |
| Free cash flow | $0.4952B | +38% QoQ |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Operating margin | FY2026 | $4.915B–$4.995B | $4.955B | Raised |
| Operating marginTOTAL_NON_GAAP | FY2026 | $4.625B–$4.695B | $4.66B | Raised |
| Revenue | FY2026 | $5.13B–$5.26B | $5.195B | Raised |
| RevenueOPSALURA | FY2026 | $1.05B–$1.1B | $1.075B | Raised |
| RevenueHEMATOLOGY_ONCOLOGY | FY2026 | $0.86B–$0.89B | $0.875B | Raised |
AI, capex & demand read
Management read
Confident
Management expressed strong confidence in the company's transition, execution, and pipeline progress, repeatedly emphasizing tangible achievements and a positive outlook.
all 5 named companies below
Companiesreturns since call
Partners
Partners
Suki
Novartis's settlement with Incyte reduced Incyte's expense base in the prior year, indicating a financial relationship between the companies.
Evidence
“The year-over-year increase reflects a lower expense base in the second quarter of 2025, resulting from the Novartis settlement of $242 million.”
Partners
Pablo
Syndax is running the Niktimbo IPF study; its data readout will be a key catalyst for a potential opt-in decision by Incyte.
Evidence
“The disclosure of the data, since they're conducting the study, will be done by Syndex.”
Partners
Pablo
Collaborating with Halozyme to optimize the subcutaneous formulation of 9A9 using their enhanced delivery technology adds optionality and could improve patient experience for the drug.
Evidence
“We recently entered a global collaboration and license agreement with Halozyme to evaluate the subcutaneous formulation of 9A9 using enhanced technology.”
Partners
Pablo
Incyte has a collaboration with Prelude for JAK2V617F assets, but owns the decision on whether to opt in based on data coming from Prelude.
Evidence
“On the Prelude Agreement, obviously those programs are managed by Prelude.”
Supply chain
Supply chain
Bill
Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting. — With a third of the market, Incyte faces direct competition from Gilead's momelotinib and possibly others; maintaining this share is key to the heme-onc portfolio's growth.
Evidence
“We currently hold approximately one third of the third line plus market.”
External signals
Supply-chain alpha · 3returns since call
Incyte's 989 MPN program may use a differentiated regulatory path with the FDA that could include novel efficacy endpoints like hemoglobin improvement, potentially setting a new precedent for MPN trials.
Evidence
“We thought and still think it's important to have a constructive dialogue with the FDA to see how we can incorporate some of these endpoints that reflect the benefit patients receive from 9A9.”
Incyte discontinuing 058 highlights increased risk in the JAK2V617F inhibitor space, but they signal a next-gen program with better data is advancing toward the clinic.
Evidence
“We decided to discontinue development 058, our lead asset in our JAK2V617F targeted pipeline, and are no longer expecting to report data later this year. ... The next generation programs have moved along very, very well.”
Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting.
Methodology & coverage
Management-only analysis. All 5 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.